Skip to content

CryoPort, Inc. CYRX FR — PP&E (Net)

Other geography segments

US
$62.96M

Similar metrics at other companies

Euronet Worldwide logo
EEFTFR — PP&E (Net)
$9.5M+15.9%
Harmonic logo
HLITFR — PP&E (Net)
$4.66M+113%
Our Bond, Inc.
 logo
OBAIFR — PP&E (Net)
$4K
Transcat logo
TRNSUS — PP&E (Net)
$51.89M+16.0%
Armstrong World Industries logo
AWIUS — PP&E (Net)
$624.7M+5.1%
Standex International logo
SXIUS — PP&E (Net)
$74.53M+32.0%

Other financials

Income statement

See full
Revenue$47.8M+16.5%
Gross profit$21.9M+17.6%
Operating income-$9.6M-33.6%
Net income-$10.5M+12.0%
EPS (diluted)-$0.25+10.7%

Balance sheet

See full
Cash & equivalents$272.9M+656%
Total debt$230.7M+293%
Total equity$495.0M+24.1%
Total assets$763.6M+9.1%

Cash flow

See full
Operating cash flow$3.7M+186%
CapEx$10.0M+215%
Free cash flow-$6.2M+16.8%

Valuation

See full
Market cap$782.24M+145%
Enterprise value$740.08M+116%
P/E10.3×
P/S4.3×+2.3×

Profitability

See full
Gross margin47.2%+1.6pp
Operating margin-21.4%-8.8pp
Net margin39.2%+22.1pp
FCF margin-13%-3.6pp

Returns & leverage

See full
Return on equity14.5%+8.6pp
Debt / equity0.5×+0.3×
Current ratio2.1×-3.5×

Where this comes from

Reported directly by CryoPort, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: CryoPort, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CryoPort, Inc.'s fr — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CryoPort, Inc.'s FR — PP&E (net)?
CryoPort, Inc. (CYRX) reported FR — PP&E (net) of $11.86M in Q4 2025.
What does FR — PP&E (net) mean?
This metric represents the net book value of tangible long-term assets, such as specialized cryogenic storage facilities, logistics infrastructure, and equipment, located within the specified geographic region. It reflects the capital investment required to support temperature-controlled supply chain operations and indicates the scale of physical capacity available to serve local biopharma and life sciences clients. Monitoring this value helps investors assess the geographic concentration of operational assets and the company's commitment to maintaining physical infrastructure in key international markets.